MEMPHASYS LIMITED. — Capital/Financing Update 2012

Aug 13, 2012

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 24] intentionally omitted <==

FOR IMMEDIATE RELEASE

NuSep Receives S$6m Investment in its Singapore Plasma Business

Sydney, Australia 14[th] August 2012 - NuSep (ASX: NSP) is pleased to advise the market that it has signed agreements with the Singapore based A-Bio Pharma Pte Ltd, a subsidiary of Luye Pharma Group (SGX:LUYE) ( Luye ) for them to invest S$6m (A$4.6m) for 10% of NuSep’s Singapore plasma fractionation subsidiary, PrIME Biologics Pte Ltd ( PrIME ). This values PrIME at S$60m (A$46m).

This investment by Luye consists of S$3.5m for the fit out and equipment of the A-Bio facility and a further S$2.5m for the facilities cGMP approval documentation. This facility was previously approved to manufacture therapeutic products by the Singapore Health Sciences Authority ( HSA ). It is expected that this previous approval will shorten the time to market for PrIME by at least 6 months.

NuSep will issue Luye with 6,000,000 shares in PrIME for this S$6m investment which represents a 10% shareholding in PrIME. NuSep currently holds the remaining 90%, but expects to sell this holding down to approximately 50% as additional investors subscribe for shares in PrIME.

Luye also has an option to increase their shareholding from the current 10% to 20% by investing a further S$6m in PrIME shares.

“This S$6m investment is a critical milestone as it represents the first investment by a pharma company into our PrIME technology and signals the start of operations in Singapore.” said NuSep Holdings’ Chairman, John Manusu.

NuSep Holdings’ Managing Director, Dr Hari Nair added that “The purchase of the A-Bio facility is expected to shorten the time to market for PrIME’s first therapeutic product by some 6 months as the A-Bio facility has previously been approved by the Singapore HSA. Further, this A$46m PrIME valuation is only for the therapeutic plasma application of NuSep’s PrIME technology and doesn’t include any other applications such as recombinant therapeutics.”

This S$6m investment by Luye will immediately allow PrIME to:

1. Activate the PrIME therapeutic plasma product business plan;

2. Establish a physical presence for Prime Biologics in Singapore;

3. Start the preparation work for the A-Bio manufacturing facility; 4. Place orders with NuSep for S$1.1m (A$840,000) of PrIME manufacturing units;

4. Place orders with NuSep for separation membranes; and

5. Begin appointment of key personnel.

Cont.

Contact Details Telephone +61 2 8415 7300 Facsimile +61 2 8415 7399

Email info@nusep.com Web www.nusep.com

NuSep Holdings Ltd 324 Burns Bay Rd Lane Cove NSW 2066

Postal Address P.O. Box 823 Lane Cove NSW 1595

ABN 33 120 047 556

– 2 –

A-Bio Facility

The A-Bio facility is located at Level 1, 41, Science Park Road, #04/11, The Gemini, Singapore Science Park II, Singapore 117610. This is approximately a 2,000m[2] therapeutic manufacturing facility that was purpose built by the Singapore Government in 2000 to meet the FDA, EMA, TGA and HSA standards and is still a state of the art cGMP registrable therapeutic manufacturing facility.

PrIME is in the process of finalising negotiations to lease the A-Bio space from Ascendas-REIT, the Singaporean landlord, and expects to complete this transaction by mid September 2012.

This facility has previously been validated by the Singapore Health Sciences Authority ( HSA ) to comply with current Good Manufacturing Production ( cGMP ). This is the regulatory approval required before therapeutic manufacturing can be undertaken. PrIME will install the PrIME fractionation units and then apply to have the facility revalidated by the HSA.

The facility is large enough that PrIME will be able to run two production lines - one for normal regulated plasma and a second for the Indian CUP product.

Below are some photos of the fit out that PrIME has acquired as part of this purchase.

==> picture [469 x 306] intentionally omitted <==

Main hall of the A-Bio Facility. There are production rooms on both sides of this facility. Cont.

– 3 –

==> picture [406 x 281] intentionally omitted <==

----- Start of picture text ----- Cont.----- End of picture text -----

A-Bio Water for Injection room

==> picture [372 x 339] intentionally omitted <==

A-Bio Reverse Osmosis water tanks. Cont.

– 4 –

ABS Novacell Biopharmaceuticals Ltd (ABS)

ABS has made significant progress in its funding, which will now be focused on establishing an Indian PrIME facility. In the meantime, ABS and NuSep are finalising the Indian CUP supply agreement. The acquisition of the A-Bio facility should enable PrIME to start processing the Indian CUP material at least 6 months ahead of the planned and budgeted timeline.

ENDS

For more information please contact:

Contact: Swapna Keskar Company Secretary +61 2 8415 7300 keskar@companymatters.com.au

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from Fraction to Function . The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

• Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

• Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

• Proteomics Software – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

• Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin .

For more information about NuSep please visit the company’s website www.NuSep.com

– 5 –

About PrIME Biologics Pte Ltd

PrIME Biologics is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. Prior to this announcement PrIME Biologics was a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). PrIME Biologics process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause ‘Mad Cow Disease’. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PrIME process will be the Currently Unprocessable Plasma which represents approximately 50% of all the plasma collected in many Asian countries.